Keytruda is a biologic medication. A biologic is made from parts of living organisms. It’s available only as a brand-name drug. Keytruda isn’t available in a biosimilar form. Biosimilars are ...

Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...

developed it and brought it to market in a host of cancer indications under the brand name Keytruda.

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Keytruda has been the best-selling medicine ... Not everything will make it to market, but I expect many brand-new approvals and label expansions through 2029. There is one crucial headwind ...

KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...

Furthermore, Keytruda will lose patent exclusivity in ... It is also expanding it thanks to acquisitions. Its most-recent, brand-new approval of Winrevair, a medicine for pulmonary arterial ...

But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta. Shadowed by the successes of ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...